Overview
Infections remain a significant concern post-kidney transplantation, impacting both morbidity and mortality rates among recipients. These infections can arise from various pathogens, with multidrug-resistant organisms like carbapenem-resistant Klebsiella pneumoniae (CRKP) posing particular challenges. Understanding the pathophysiology, epidemiology, clinical presentation, diagnosis, and management of these infections is crucial for optimizing patient outcomes. This guideline synthesizes current evidence to provide clinicians with a comprehensive framework for addressing post-transplant kidney infections.
Pathophysiology
The pathophysiology of post-transplant kidney infections involves complex interactions between the immune system and invading pathogens. Recent studies highlight the roles of chemokines such as CXCL9 and CXCL13 in mediating immune cell recruitment and activation, which are critical in the context of transplant infections [PMID:33725942]. CXCL9, often associated with T-cell recruitment, and CXCL13, linked to B-cell homing, contribute to the inflammatory milieu that can exacerbate or perpetuate infections. These chemokines not only facilitate the immune response but also potentially indicate a heightened state of immune activation that may predispose transplant recipients to opportunistic infections. The interplay between these chemokines and the unique immunosuppressive environment post-transplantation underscores the need for monitoring these biomarkers to predict and manage infection risks effectively.
Epidemiology
Post-transplant infections are a substantial burden, contributing significantly to healthcare costs and patient morbidity and mortality. Epidemiological data emphasize the critical need for robust predictive tools to identify high-risk patients [PMID:33725942]. Notably, certain pathogens like CRKP have emerged as significant threats, with infections occurring even in the absence of recent travel, suggesting local or nosocomial transmission risks [PMID:31527031]. A study spanning 2013 to 2017 identified Klebsiella pneumoniae as the predominant cause of multidrug-resistant Enterobacteriaceae (CRE) infections, with 46 out of 47 cases attributed to this pathogen [PMID:30680569]. These findings highlight the prevalence of specific resistant strains and underscore the importance of surveillance and infection control measures in transplant centers to mitigate transmission risks.
Clinical Presentation
The clinical presentation of post-transplant kidney infections can vary widely but often includes systemic manifestations reflecting the severity and site of infection. Urinary tract infections (UTIs) are among the most common, accounting for approximately 54.3% of reported cases [PMID:30680569]. However, more severe presentations, such as bloodstream infections and intra-abdominal infections, are also observed. For instance, a case report detailed a patient with CRKP isolated from both blood and the abdominal cavity, indicating that these infections can affect multiple organ systems simultaneously [PMID:31527031]. Such multi-site involvement underscores the need for comprehensive diagnostic evaluations, including blood cultures, urine analysis, and imaging studies, to accurately identify the extent and nature of the infection.
Diagnosis
Diagnosing post-transplant infections requires a multifaceted approach, integrating clinical symptoms with laboratory and microbiological evidence. Biomarkers such as CXCL9 and CXCL13 show promise in identifying patients at risk for infections due to their roles in immune cell recruitment and activation [PMID:33725942]. Elevated levels of these chemokines may serve as early indicators of impending infection, guiding closer monitoring and preemptive interventions. Additionally, accurate identification of the infecting pathogen is crucial, particularly in cases involving multidrug-resistant organisms like CRKP. Comprehensive genotyping, as demonstrated in a case study where two distinct ST types of CRKP were identified, is essential for tailoring appropriate antimicrobial therapy and understanding transmission dynamics [PMID:31527031]. This approach ensures targeted treatment strategies that account for genetic variations and resistance profiles.
Management
The management of post-transplant infections, especially those caused by multidrug-resistant organisms, demands a tailored and aggressive approach. Monitoring chemokines like CXCL9 and CXCL13 can provide clinicians with valuable insights into the immune response and guide therapeutic decisions [PMID:33725942]. In managing CRKP infections, the choice of antimicrobial agents is critical. A case report illustrated successful bacterial clearance using a combination regimen including cefiderocol, ceftazidime-avibactam, and polymyxin B, highlighting the importance of using agents with activity against resistant strains [PMID:31527031]. Furthermore, the use of aminoglycosides, such as amikacin, has shown significant clinical success, with a notable difference in treatment outcomes between those treated with and without aminoglycosides (78.9% vs. 37.0% success rates, respectively) [PMID:30680569]. These findings suggest that aminoglycosides may play a protective role in combating resistant infections, although individual patient factors and resistance patterns must be considered in treatment planning.
Complications
Despite aggressive management, post-transplant infections can lead to severe complications that threaten patient survival. Ischemic colitis and multiorgan failure, as seen in a case involving CRKP infection, exemplify the potential for catastrophic outcomes [PMID:31527031]. Additionally, comorbidities such as diabetes mellitus have been identified as significant risk factors for treatment failure, emphasizing the need for comprehensive risk stratification and tailored management strategies [PMID:30680569]. Clinicians must remain vigilant for signs of systemic involvement and organ dysfunction, employing multidisciplinary approaches to address both the primary infection and its complications effectively.
Key Recommendations
By adhering to these recommendations, clinicians can enhance the surveillance, diagnosis, and management of post-transplant kidney infections, ultimately improving patient outcomes and reducing morbidity and mortality associated with these infections.
References
1 Yan L, Li YM, Li Y, Bai YJ, Wan ZL, Fan JW et al.. Role of serum CXCL9 and CXCL13 in predicting infection after kidney transplant: A STROBE study. Medicine 2021. link 2 Contreras DA, Fitzwater SP, Nanayakkara DD, Schaenman J, Aldrovandi GM, Garner OB et al.. Coinfections of Two Strains of NDM-1- and OXA-232-Coproducing Klebsiella pneumoniae in a Kidney Transplant Patient. Antimicrobial agents and chemotherapy 2020. link 3 Freire MP, de Oliveira Garcia D, Cury AP, Francisco GR, Dos Santos NF, Spadão F et al.. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2019. link